Gemcitabine and vinorelbine: treatment option in recurrent platinum – resistant ovarian cancer

Main Article Content

Doaa Ali Mohammad Sharaf Eldeen
Abdelgawad Elmetwaly Abdelgawad

Keywords

Abstract

Background and aim of the work: to evaluate the efficacy and toxicity of vinorelbine plus gemcitabine combination in patients who had recurrent platinum resistant ovarian cancer. Patients and method: twenty one patients with recurrent platinum resistant ovarian cancer were designated to receive vinorelbine 25 mg/mplus gemcitabine 1 gm/m2 on 1st and 8th day of each 21 – day cycle. Results: The Median age was 56 years (range 38-67). One patient (4.8%) achieved complete response and 5 patients (23.8%) had partial response with an overall response rate 28.57%. Median time to progression was 4 months and median overall survival was 11 months. Toxicity was modest and generally tolerated. Nine events (42.85%) of grade 3 hematological toxicity and only one event (4.57%) grade 3 non hematologic toxicity were observed. Conclusion: The combination of gemcitabine and vinorelbine is a moderately active regimen in recurrent platinum resistant ovarian cancer with  an acceptable toxicity  rating it as  an option in treatment of such disease.

Downloads

Download data is not yet available.
Abstract 18 | PDF Downloads 12